178 related articles for article (PubMed ID: 32429788)
1. Wixela Inhub: Dosing Performance
Cooper A; Parker J; Berry M; Wallace R; Ward J; Allan R
J Aerosol Med Pulm Drug Deliv; 2020 Dec; 33(6):323-341. PubMed ID: 32429788
[No Abstract] [Full Text] [Related]
2. Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma.
Ng D; Kerwin EM; White MV; Miller SD; Haughie S; Ward JK; Allan R
J Aerosol Med Pulm Drug Deliv; 2020 Apr; 33(2):99-107. PubMed ID: 31634023
[No Abstract] [Full Text] [Related]
3.
Shepherd T; Kennett M; Cooper A; Parkinson A
J Aerosol Med Pulm Drug Deliv; 2022 Jun; 35(3):154-165. PubMed ID: 34726509
[No Abstract] [Full Text] [Related]
4. Wixela Inhub: A Generic Equivalent Treatment Option for Patients with Asthma or COPD.
Donohue JF; Burgoyne DS; Ward JK; Allan R; Koltun A; Cooper A
Pulm Ther; 2021 Jun; 7(1):47-57. PubMed ID: 33284384
[TBL] [Abstract][Full Text] [Related]
5. Usability and Robustness of the Wixela Inhub Dry Powder Inhaler.
Allan R; Canham K; Wallace R; Singh D; Ward J; Cooper A; Newcomb C
J Aerosol Med Pulm Drug Deliv; 2021 Apr; 34(2):134-145. PubMed ID: 32865454
[No Abstract] [Full Text] [Related]
6. Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies.
Haughie S; Allan R; Wood N; Ward J
J Aerosol Med Pulm Drug Deliv; 2020 Feb; 33(1):34-42. PubMed ID: 31364911
[No Abstract] [Full Text] [Related]
7. Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease.
Feldman WB; Kesselheim AS; Avorn J; Russo M; Wang SV
Ann Intern Med; 2023 Aug; 176(8):1047-1056. PubMed ID: 37549393
[TBL] [Abstract][Full Text] [Related]
8. The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device.
Tashkin DP; Ohar JA; Koltun A; Allan R; Ward JK
Pulm Med; 2021; 2021():8881895. PubMed ID: 33815843
[TBL] [Abstract][Full Text] [Related]
9. In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial.
Jõgi R; Lähelmä S; Vahteristo M; Happonen A; Haikarainen J
J Aerosol Med Pulm Drug Deliv; 2019 Apr; 32(2):88-98. PubMed ID: 30300557
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
11. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
[TBL] [Abstract][Full Text] [Related]
13. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers.
Buttini F; Brambilla G; Copelli D; Sisti V; Balducci AG; Bettini R; Pasquali I
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):167-78. PubMed ID: 26355743
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of fluticasone propionate and salmeterol delivered as a combination dry powder via a capsule-based inhaler and a multi-dose inhaler.
Mehta R; Daley-Yates PT; Jenkins K; Bianco J; Stylianou A; Louey MD; Chan RH
Pulm Pharmacol Ther; 2014 Oct; 29(1):66-73. PubMed ID: 25035069
[TBL] [Abstract][Full Text] [Related]
15. Optimizing inhalation therapy in the aspect of peak inhalation flow rate in patients with chronic obstructive pulmonary disease or asthma.
Hua JL; Ye XF; Du CL; Xie N; Zhang JQ; Li M; Zhang J
BMC Pulm Med; 2021 Sep; 21(1):302. PubMed ID: 34560863
[TBL] [Abstract][Full Text] [Related]
16. The inhalation characteristics of patients when they use different dry powder inhalers.
Azouz W; Chetcuti P; Hosker HS; Saralaya D; Stephenson J; Chrystyn H
J Aerosol Med Pulm Drug Deliv; 2015 Feb; 28(1):35-42. PubMed ID: 24815999
[TBL] [Abstract][Full Text] [Related]
17. Ventolin Diskus and Inspyril Turbuhaler: an in vitro comparison.
Broeders ME; Molema J; Burnell PK; Folgering HT
J Aerosol Med; 2005; 18(1):74-82. PubMed ID: 15741776
[TBL] [Abstract][Full Text] [Related]
18. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
Grant AC; Walker R; Hamilton M; Garrill K
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
[TBL] [Abstract][Full Text] [Related]
19. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics.
Tarsin WY; Pearson SB; Assi KH; Chrystyn H
Int J Pharm; 2006 Jun; 316(1-2):131-7. PubMed ID: 16584855
[TBL] [Abstract][Full Text] [Related]
20. Clinical Bioequivalence of OT329 SOLIS and ADVAIR DISKUS in Adults with Asthma.
Longphre MV; Getz EB; Fuller R
Ann Am Thorac Soc; 2017 Feb; 14(2):182-189. PubMed ID: 27849125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
